AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...

The popular harem action series High School DxD is getting a new spinoff manga series based on the descendant of Miyamoto ...

Get detailed information about the ProShares UltraShort Dow30 ETF. View the current DXD stock price chart, historical data, premarket price, dividend returns and more.

The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan in breast and lung cancer. The ...

በየሳምንቱ በባለሙያዎች የሚመከረው ያህል የአካል ብቃት እንቅስቃሴ ለማድረግ ብዙዎች ይቸገራሉ። የአካል ብቃት እንቅስቃሴ ለልብ ጤና ጠቃሚ ነው። የደም ...

Ifinatamab deruxtecan (I-DXd) demonstrated a 48.2% ORR and 87.6% DCR in previously treated ES-SCLC patients, with rapid and durable responses. Median PFS was 4.9 months, and median OS was 10.3 months, ...

According to analysts, the new data could present a path to accelerated approval for ifinatamab deruxtecan, a product of Merck and Daiichi Sankyo’s troubled ADC partnership. Nearly half of patients ...

Also, such filings may not represent all regulatory or legal actions against a firm or advisor. For more detailed information on Dxd Capital ’s conduct, please visit Finra’s BrokerCheck, the SEC’s ...